Core Viewpoint - LENZ Therapeutics is preparing to report its fourth quarter and full year 2024 financial results and recent corporate highlights on March 19, 2025 [1] Company Overview - LENZ Therapeutics is a pre-commercial biopharmaceutical company focused on developing and commercializing the first and only aceclidine-based eye drop for improving near vision in presbyopia patients [3] - The product candidate, LNZ100, is a preservative-free, single-use, once-daily eye drop containing aceclidine [3] - LNZ100 was evaluated in the Phase 3 CLARITY study as a potential therapy for presbyopia, which affects approximately 1.8 billion people globally and 128 million people in the United States [3] - The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of August 8, 2025, for LNZ100 [3] - The company aims to provide an ideal pharmaceutical solution for presbyopia that enhances vision for "all eyes, all day" [3] - LENZ Therapeutics is headquartered in San Diego, California [3]
LENZ Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights on March 19, 2025